Clinical Report: EBMT 2024 Activity Report on HCT and CAR-T Therapies
Overview
The EBMT 2024 report marks a significant milestone with over one million hematopoietic cell transplants (HCTs) recorded since 1990. In 2024, HCT activity showed a slight overall decline, while CAR-T therapies increased by 24.5%, highlighting evolving trends in cellular treatments.
Background
Hematopoietic cell transplantation (HCT) is a critical therapeutic option for various hematological and immunological disorders. The EBMT activity survey has been instrumental in tracking HCT trends and advancements in cellular therapies across Europe. Understanding these trends is essential for optimizing treatment strategies and ensuring equitable access to emerging therapies.
Data Highlights
Year
Total HCTs
Allogeneic HCTs
Autologous HCTs
CAR-T Therapies
2024
47,204
21,023
26,181
6,082
Key Findings
Over one million HCTs have been reported since 1990.
In 2024, 47,204 HCTs were performed, a slight decrease of 1.1% from 2023.
Allogeneic HCTs increased by 2.6%, reaching the highest annual activity to date.
CAR-T therapy utilization rose by 24.5%, with 6,082 patients treated in 2024.
Major indications for allo-HCT included myeloid malignancies (62%) and lymphoid malignancies (~24%).
From 2025, separate reporting for adult and pediatric HCT activity will be implemented.
Clinical Implications
The increase in CAR-T therapies suggests a shift in treatment paradigms for hematological malignancies, emphasizing the need for clinicians to stay updated on evolving indications and guidelines. The slight decline in overall HCT activity may prompt further investigation into barriers to access and treatment optimization.
Conclusion
The EBMT 2024 report underscores the resilience and adaptability of HCT and CAR-T therapies in clinical practice, reflecting ongoing advancements in cellular treatments. Continued monitoring and adaptation of practices will be essential as the landscape of hematological therapies evolves.
by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda
